

Modified Form 1449/PTO				Application Number		10/692,764	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date		October 24, 2003	
				First Named Inventor		Levy et al.	
				Group Art Unit		1633	
				Examiner Name		Janet L. Epps Smith	
				Attorney Docket Number		16534-539001US	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropri ate
	A56	2009/0118269 A1	05/07/09	Berniac et al.	514	231.5	
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	
	B6	WO 03/005971 A2	PARATEK PHARMACEUTICALS, INC.		01/23/03		
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C17	"FAMILIES OF SPINAL MUSCULAR ATROPHY AND PARATEK PHARMACEUTICALS EXPAND DRUG DISCOVERY COLLABORATION FOR SPINAL MUSCULAR ATROPHY", http://www.paratekpharm.com/m_press.html , XP-002492415, 2 pages (2007)					
	C18	"SMA SUMMIT ON DRUG DEVELOPMENT, SESSION 7: IDENTIFICATION OF TETRACYCLINE COMPOUNDS THAT CORRECT DEFECTIVE SMN2 SPLICING", http://www.fsma.org/research/clinical/smadrugsummit/smadrugsummitslides/ , (2007)					
	C19	Sumner, C.J. "THERAPEUTICS DEVELOPMENT FOR SPINAL MUSCULAR ATROPHY", <i>J. Am. Soc. Exp. NeuroTherap.</i> , 3(2):235-245 (2006)					

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.